Furthermore, MPT0G413/bortezomib combination decreased VEGF and IL-6 expression and secretion in the BM microenvironment, thus enforcing MM cell cycle arrest [119] (Figure 5). This evidence concerns the gene IL6 and Miyoshi myopathy.